Richard Fengl

Executive Director, Business Development at SK pharmteco

Richard Fengl, Ph.D., has a diverse work experience in the pharmaceutical industry. Richard currently holds the role of Executive Director, Business Development at SK Pharmteco since 2023. Prior to that, they served as the Director, Business Development at Axplora from 2019 to 2023. Richard also worked as the Senior Director Business Development at Rohner Inc. from 2018 to 2019. From 2009 to 2017, they were the Director Business Development at Siegfried (USA), where they successfully established and grew accounts and utilized their pharmaceutical technology knowledge to enhance customer value. Before that, they served as the Director of Business Development at Asymchem Laboratories, focusing on improving customer interaction and increasing business revenues. Richard also held the position of Director, North American Sales at Piramal Healthcare (purchased Avecia), where they brought in projects for different sites. Earlier in their career, they worked at Avecia as a Key Account Manager and at Eastman Chemical Company as a Principal Research Scientist, where they were involved in various technical and development roles.

Richard Fengl, Ph.D. received their Bachelor of Science degree in Chemistry from the College of Charleston. Richard then proceeded to pursue their Ph.D. in Organic Chemistry at Emory University.

Links


Org chart


Teams


Offices

This person is not in any offices


SK pharmteco

Headquartered in Rancho Cordova, California, SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. Built on 80 years of experience, our global operations have the capability and capacity to support client needs from development through commercial production. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group.